BiomX Inc. (PHGE) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the Biomix third quarter 2024 financial results conference call. At this time, all participants are in a listen-only mode. The question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce Marina Wolfson, Chief Financial Officer. Thank you. You may begin. Thank you, and welcome to the Biomics conference call to review the company's third quarter 2024 financial results and provide an update on our business and programs. Later today, we will file the quarterly report on Form 10Q with the Securities and Exchange Commission. In addition, the press release became available at 6.30 a.m. Eastern Time today and can be found on our website at biomics.com. A replay of this call will also be available on the Investors section of our website. As we begin, I'd like to review the Safe Harbor provision. All statements on this call that are not factual historic statements may be deemed forward-looking statements. For instance, we are using forward-looking statements when we discuss on the conference call the sufficiency of the company's cash, our pipeline, the design, recruitment, aim, expected timing, and interim and final results of our preclinical and clinical trials, the potential benefits of our product candidates, and the potential safety or efficacy of our product candidates BX004 and BX211. In addition, passing current preclinical and clinical results, as well as compassionate use, are not indicative and do not guarantee future success of our clinical trials. Except as required by law, we do not undertake to update forward-looking statements. The fu...